Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer (2019) Fasching P, Huang M, Cortes J, Zhao J, O'Shaughnessy J, Hu P, Haiderali A, et al. Conference contribution Comparative analysis of tumour mutational burden (TMB) prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer (UBC) (2019) Eckstein M, Hartmann A, Strissel P, Strick R, Wach S, Taubert H, Wullich B, et al. Conference contribution Salivary and hair cortisol as biomarkers of emotional and behavioral symptoms in 6–9 year old children (2019) Golub Y, Kuitunen-Paul S, Panaseth K, Stonawski V, Frey S, Steigleder R, Grimm J, et al. Journal article Erratum: Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature communications (2019) 10 1 (431)) (2019) Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, et al. Journal article, Erratum Nab-paclitaxel improves disease-free survival in early breast cancer: GBG 69–Geparsepto (2019) Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, et al. Journal article Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study (2019) Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, et al. Journal article A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study (2019) Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al. Journal article Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis (2019) Yarmolinsky J, Relton CL, Lophatananon A, Muir K, Menon U, Gentry-Maharaj A, Walther A, et al. Journal article KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer (2019) Mamounas EP, Geyer CE, Huang CS, Mano MS, Loibl S, Untch M, Wolmark N, et al. Conference contribution Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study (2019) Wallwiener M, Nabieva N, Feisst M, Fehm T, De Waal J, Rezai M, Baier B, et al. Journal article